What Providers Review Before Prescribing Peptides
When your intake reaches a licensed provider, it is not a rubber stamp. There is a specific list they run down before any peptide is approved: the conditions that change whether a peptide is safe, the medication classes that have to be cross-checked, and the reasons an order gets sent back or declined. Here is that list, from the provider’s side of the screen.
In this article
Key Takeaways
- A peptide intake at PeRx is reviewed by a licensed provider, not auto-approved. The review is a defined checklist, not a formality.
- The provider screens four things: is this peptide safe for your history, does it collide with your medications, is the dose right for you, and is it even the right peptide for your goal.
- Specific medication classes get a closer look: diabetes medication and insulin, blood-pressure and cardiovascular drugs, anticoagulants, immunosuppressants, and current hormone therapy. None is an automatic no; each is a prompt to look closer.
- An intake can end four ways: approved as requested, approved with a different protocol, sent back for more information, or declined. Paying for an assessment does not guarantee a prescription.
- No labs are required to start. If your history makes labs useful, the provider asks for them before prescribing, not after.
What Happens When Your Intake Arrives
The review is the product
Most peptide content describes the patient’s steps: fill out the form, get the vials, start injecting. This guide is written from the other side of the screen. When your assessment reaches a licensed provider, there is a specific checklist they run before approving anything. Knowing what is on that list tells you more about whether a peptide service is legitimate than any marketing copy can.
At PeRx the process starts with a short online health assessment. It takes about five minutes and asks about your goals, your medical history, your current medications, and your allergies. None of that is busywork. Every field exists because a provider uses it to make a decision. The assessment is the input. The review is where the medicine happens.
Async telehealth, where a provider reviews your intake rather than meeting you live, is an established and regulated way to prescribe. The Federation of State Medical Boards has been explicit that a valid physician-patient relationship can be formed through asynchronous telemedicine, so long as the standard of care is met and the provider evaluates the appropriateness and safety of each prescription. The format is online. The clinical bar is the same as anywhere else.
Federation of State Medical Boards. Report of the FSMB Workgroup on Telemedicine (April 2022): a physician-patient relationship may be established via synchronous or asynchronous telemedicine so long as the standard of care is met. View study
The Review Checklist, Item by Item
Strip away the software and a prescribing review comes down to four questions. A provider answers all four before an order is approved. The first three protect you from harm. The fourth protects you from wasting months on the wrong tool.
| What the provider checks | What they are looking for | Why it matters | |
|---|---|---|---|
| Is it safe for your history | Is this peptide safe for your history | Active or recently treated cancer for anything that raises IGF-1; pregnancy or breastfeeding; uncontrolled diabetes or hypertension; significant cardiovascular, kidney, or liver disease; undiagnosed symptoms that need a workup first. | Some conditions change whether a peptide should be prescribed at all. A vendor has no way to know any of this. A provider asks before writing the order. |
| Drug interactions | Will it collide with your medications | Your full medication and supplement list, with particular attention to diabetes medication, blood-pressure and cardiovascular drugs, anticoagulants, immunosuppressants, and hormone therapy. | Most interactions are manageable, but only once they are identified. Identifying them is a clinical step, not something a vial label can do. |
| Right dose | What dose is right for you | A starting dose calibrated to your size, goals, and history, rather than a number copied from a forum protocol written for someone else. | A generic dose can be too high, too low, or simply guessed. Calibration is part of what a prescription is for. |
| Right peptide | Is this even the right peptide | Whether the peptide you requested actually fits your stated goal, or whether a different one fits better. | The peptide a patient asks for is sometimes not the one that suits their situation. Catching that early saves months. |
The IGF-1 question, concretely
Growth-hormone-secretagogue peptides such as CJC-1295, Ipamorelin, Sermorelin, and Tesamorelin work by raising growth hormone, which raises IGF-1. For most healthy adults that is the intended effect. For someone with an active or recently treated cancer, raising a growth signal is a reason to pause and reconsider. A patient on a research-chemical site gets no prompt to think about this. On a reviewed intake, it is one of the first things a provider checks. That single question is the kind of thing the review exists for.
Allergies and prior reactions get their own look. If you have reacted to a peptide before, or to a preservative or excipient used in compounded injectables, that belongs in the intake and it changes the plan. The same goes for a history of injection-site problems. None of this is dramatic. It is the ordinary diligence of matching a medication to a person, which is exactly the part a vendor cannot do for you.
The Medications We Look At Closely
Competitors tend to compress this into a single line: "disclose your medications." That is true but not useful. Here is what a provider actually does with that list. Certain classes get a second look, not because they rule a peptide out, but because they are the ones most likely to interact with how a peptide behaves in the body.
| Medication class | Why a provider flags it | Usual outcome | |
|---|---|---|---|
| Diabetes meds / insulin | Diabetes medication and insulin | Peptides that affect growth hormone can be relevant to blood-sugar regulation. The provider confirms the combination is reasonable and the dose accounts for it. | Usually fine with attention to dosing; occasionally a reason to adjust the plan. |
| Blood pressure / cardiovascular | Blood-pressure and cardiovascular drugs | Some peptides influence blood pressure or fluid balance, which matters alongside cardiovascular medication. | Reviewed case by case; rarely a hard stop on its own. |
| Anticoagulants | Blood thinners and anticoagulants | Injectable therapy plus anticoagulation is worth confirming, mostly around injection technique and bruising. | Typically proceeds with guidance, not a denial. |
| Immunosuppressants | Immunosuppressants and steroids | These change the backdrop a peptide is working against and can matter for healing-focused peptides. | Reviewed in the context of the underlying condition. |
| Hormone therapy | Current hormone therapy | Hormone therapy interacts with how growth-hormone peptides are evaluated and with overall goals. | Factored into peptide selection and dose. |
The honest summary: almost none of these is an automatic no. They are prompts to look closer. The reason the full list matters, including over-the-counter supplements people forget to mention, is that the provider would rather identify a manageable interaction up front than have you discover it on your own later.
Approved, Sent Back, or Declined
This is the part almost no one writes about. An intake does not have two outcomes (yes or no). It has four. Understanding the middle two is the difference between thinking of a peptide service as a store and understanding it as a clinical decision.
| Outcome | What it means | What happens next | |
|---|---|---|---|
| Approved as requested | Approved as requested | Your history is clear, your medications check out, and the peptide fits your goal. | The protocol is prescribed and compounded at a 503A pharmacy. Vials ship ready to use. |
| Approved, different protocol | Approved, but a different protocol | A peptide is appropriate for you, but not the exact one or dose you asked for. | The provider prescribes the better-fitting option and explains the change. |
| More information needed | We need more information | Something in your intake raises a question that has to be answered before it is safe to prescribe. | The provider requests clarification or, occasionally, recent labs, then completes the review. |
| Declined | Not a candidate right now | A condition, medication, or risk makes prescribing the wrong call, either for now or in general. | The order is declined. Paying for the assessment does not buy a prescription. |
Paying is not the same as being approved
It is worth stating plainly because some services blur it. Completing an assessment and paying a fee starts a review. It does not guarantee the outcome. If the clinically correct answer is no, or not yet, a legitimate provider gives you that answer. A service that approves everyone who pays is not actually reviewing anything.
Why We Do Not Just Approve Everyone
A research-chemical vendor optimizes for the sale. Their incentive runs in one direction. A licensed provider is professionally and legally accountable for the decision, which means they carry a duty the vendor does not: to decline when declining is correct. Being told "this is not the right peptide for what you are describing," or "let us hold off until this other issue is addressed," is not the service failing. It is the service working.
That accountability is also why a prescription creates a real medical record and a research-chemical purchase does not. If something goes wrong with a vial you bought labeled "not for human use," there is no provider who reviewed it and no record of what you took. The review is the thing standing in that gap. For the other half of quality, what the pharmacy guarantees about the vial itself, see our guide on how to read a peptide COA and the research vs prescription comparison.
After Approval: Protocol and Renewal
It is worth being clear about what happens after a yes, because this is another place marketing tends to overpromise. PeRx providers do not coach you day to day or adjust your dose on a rolling basis. The medical involvement is concentrated where it changes outcomes: the prescribing decision up front, and a brief renewal check-in at the end of each 100-day prescription cycle before the next one opens.
What the process actually looks like
Step 1
You complete a short online health assessment covering goals, history, current medications, and allergies. No labs are required to start, and there is no in-person visit.
Step 2
A licensed provider reviews your intake against the checklist above: safety, interactions, dose, and whether the peptide fits your goal.
Step 3
If appropriate, the provider prescribes your protocol and it is compounded at a 503A pharmacy. Vials ship ready to use, refrigerated, with no patient-side mixing.
Step 4
You manage routine dosing. At the end of each 100-day cycle, a brief renewal check-in with your provider opens the next window. The medical touchpoints are the prescribing decision and the renewal, not constant supervision.
The providers who review PeRx prescriptions are named and credentialed, not an anonymous panel. You can see who they are on our team page. That is part of the point. The person deciding whether a medication is right for you should be someone you can actually identify.
Frequently Asked Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
Pinealon, PE-22-28 & Selank Guide (2026)
Three peptides, three layers of brain support. Pinealon restores sleep architecture through pineal gland regulation. PE-22-28 drives neurogenesis by blocking the TREK-1 potassium channel. Selank calms anxiety through GABA modulation without sedation or dependence. Together they rebuild, grow, and protect neural tissue from three independent angles.
Is CJC-1295/Ipamorelin FDA Approved? (2026 Answer)
The short answer is no. CJC-1295 and Ipamorelin are not FDA-approved drugs. They are compounded medications, prescribed by licensed providers and prepared by regulated pharmacies. Here is what that actually means for you, how it compares to FDA-approved peptides, and why the distinction matters less than most people think.
Is Sermorelin FDA Approved? Yes Until 2008
Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.
Start with a review, not a checkout
Take our short health assessment. A licensed provider reviews every intake against the checklist in this guide, screens for safety and interactions, and prescribes only what fits your situation. No labs required to start. Approved orders ship overnight, refrigerated, ready to use.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.
Reviewed by Dr. Cory Mellon, MD · Last reviewed June 2026